US 11,987,583 B2
Fused triazolo-pyrimidine compounds having useful pharmaceutical application
Sergei Romanov, Chapel Hill, NC (US); Robert Greenhouse, Newark, CA (US); and Nikolai Sepetov, Los Gatos, CA (US)
Assigned to PIKSci INC., Ontario (CA)
Filed by PIKSci Inc., Toronto (CA)
Filed on Jun. 30, 2021, as Appl. No. 17/364,482.
Application 17/364,482 is a continuation of application No. 16/496,943, granted, now 11,066,410, previously published as PCT/US2018/024060, filed on Mar. 23, 2018.
Claims priority of provisional application 62/601,501, filed on Mar. 24, 2017.
Prior Publication US 2021/0323969 A1, Oct. 21, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/519 (2006.01); A61P 35/00 (2006.01); C07D 487/04 (2006.01); C07D 519/00 (2006.01)
CPC C07D 487/04 (2013.01) [A61P 35/00 (2018.01); C07D 519/00 (2013.01)] 15 Claims
 
1. A method of treating multiple myeloma, comprising:
administering a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof:

OG Complex Work Unit Chemistry
wherein
R1 is alkyl, heterocyclyl, aryl, or heteroaryl, provided R1 is not cyclohexyl,
R2 is —N═CH-alkyl, —N═CH-aryl or —N═CH-heteroaryl,
R3 and R4 together with the nitrogen to which they are attached form a mono or bi-cyclic heterocyclyl each of the mono or bi-cyclic heterocyclyl is optionally substituted with one, two, three, or four groups selected from C1-C6 alkyl.